ERBB2 and breast carcinoma: In HR + HER2 + breast cancer, extended therapy with neratinib, an irreversible pan-HER2 inhibitor, improves iDFS at 5 years by 5.1% (HR 0.58) and OS at 8 years by 2.1% (HR 0.79) following trastuzumab-based adjuvant therapy [56] (Fig. 3).